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Available online 5 June 2016Background: Out-of-hospital deaths due to a ﬁrst myocardial infarction (MI) are frequent and a big challenge for
prevention. Increased knowledge about factors inﬂuencingMI fatality is needed.Metabolic risk factors have been
studied in relation to MI fatality in-hospital but studies considering also out-of-hospital deaths are few.
Aim: To assess howdiabetes and othermetabolic risk factors associatewith deathwithin 7 days afterﬁrst timeMI
among subjects aged between 45 and 70 identiﬁed in Stockholm County 1992–1994.
Methods: Data were collected using questionnaires (close relatives of fatal cases were asked to ﬁll the question-
naire), physical examinations, national registers and autopsy reports. Risk ratios (RR) of 7-day MI fatality with
95% conﬁdence intervals (CI) associatedwith the risk factors under study were calculated using binomial regres-
sion with log link.
Results: Out of 1905 ﬁrst time MI cases included, 524 died within 7 days. After adjustments for age, sex, current
smoking, education and general comorbidity, diabetes, but not hypertension and hyperlipidemia, was associated
with MI fatality (RR 1.68, 95% CI 1.20–2.28). Overweight, as compared to normal BMI, was inversely associated
withMI fatality (multiple adjustedRR0.68, 95%CI 0.49–0.94); obesity results pointed in the samedirection (mul-
tiple adjusted RR 0.79, 0.52–1.16).
Conclusions: In this population-based inception cohort study, diabetes but not hypertension and hyperlipidemia
were associatedwith MI fatality. This further emphasizes the importance of diabetes as a cardiovascular risk fac-
tor and the need for close surveillance of diabetic patients. Overweight was however associated with decreased
MI fatality.










Although coronary heart disease (CHD) mortality shows a declining
trend in different populations [1–4], the proportion of individuals who
die within 28 days from the onset of a ﬁrst myocardial infarction (MI)
is still approximately 30% [1,2]. The majority of these individuals die
out-of-hospital [1]. The knowledge about determinants of MI fatality is
limited. Among the traditional cardiovascular risk factors studied in re-
lation to MI fatality, diabetes has gained most attention.
Diabeteswas consistently identiﬁed as an important risk factor of in-
hospital MI fatality [5–12]. Studies that considered also out-of-hospital
CHD deaths (referred to here as population based studies) either sup-
port diabetes as a risk factor of MI fatality [9,10] or could not assess it).
land Ltd. This is an open access articldue to limited sample size [13,14]. None of the population based studies
used a narrow deﬁnition of MI death out-of-hospital; they used any
CHDor sudden death [9,10,13,14]. Further, none of these studies consid-
ered overweight and obesity as potential confounding factors. Consider-
ing the substantial proportion of CHD deaths occurring out-of-hospital
[15], further studies are needed to clarify the role that diabetes has in
MI fatality. It is also important to elucidatewhether othermetabolic fac-
tors such as hypertension, hyperlipidemia, overweight, and obesity in-
ﬂuence MI fatality. Among previous investigations of these factors,
only a limited number considered out-of-hospital CHD death, and they
regarded only hypertension [13–14,16] and hyperlipidemia [13]. Re-
sults point in different directions.
Typically, previous studies of determinants of MI fatality that did
consider out-of-hospital CHDdeath are cohort studieswhere the assess-
ment of each respectivemetabolic risk factor took place many years be-
fore the MI event. Thus, exposure information may not accuratelye under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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vious studies rarely report the proportion of autopsies forming basis for
the classiﬁcation of MI death. Differentiation between fatal MI and sud-
den death due to other reasons than MI usually requires autopsy [17].
In thepresent study,we aimed to assess howdiabetes, hypertension,
hyperlipidemia, overweight, and obesity, measured close in time to a
ﬁrst MI event, are associated with MI fatality. Although each of these
metabolic risk factors has previously been studied in relation toMI fatal-
ity, resultsweremost often based solely on admittedMI patients, which
may have affected generalizability of results. The present study con-
siders both in- and out-of-hospital deaths. The data forming basis for
our study were collected between 1992 and 1994 when the rate of au-
topsies in Sweden was high: 72% of the fatal MI cases included were
ascertained through autopsy.
2. Materials and methods
2.1. Study population
This study is based on material from the Stockholm Heart Epidemi-
ology Program (SHEEP), a study of risk factors for MI performed in
Stockholm County among men and women 45–70 years old, residing
in Stockholm and who were Swedish citizens. Details about the SHEEP
design, including criteria for diagnosis ofMI, have earlier been described
[18]. Eligible for inclusion in the present inception cohort studywere all
individuals suffering anMI between 1992 and 1994 in the deﬁned study
population without previous hospitalization for MI (International Clas-
siﬁcation of Diseases, ICD, versions 8 and 9, codes 410 or 412 according
to data from the National Patient Register). An additional effort to ex-
clude individuals with previous MI involved asking (using question-
naires) participants whether they had previously been hospitalized
due to MI. Those who answered “yes” were phoned and excluded if
the prior MI diagnosis was conﬁrmed. MI cases with previous MI, as
identiﬁed from autopsy reports, but without previous hospitalization
for MI recorded were not excluded. Thus, our study is restricted to
ﬁrst known MI cases.
In the SHEEP, 2246 MI cases were identiﬁed with a ﬁrst time docu-
mentedMI using three sources: 1) coronary units and internalmedicine
wards for acute care in all Stockholm hospitals; 2) the National Patient
Register (ICD 9 code 410 as main or secondary diagnosis); and
3) death certiﬁcates (ICD 9 code 410 as main or contributory cause of
death) [18]. In the original SHEEP study design, fatal MI was deﬁned
as death within 28 days. In 28-day fatal MI cases, MI as a cause of
death was ascertained by autopsy data in 69%. The remaining cases
were carefully evaluated by the SHEEP secretariat using any available
information on disease history and death circumstances. Among the
identiﬁed cases, 1643 MI cases survived at least 28 days and were con-
sidered as non-fatal cases, whereas 603 were considered fatal.
For the main analyses of the current study, we considered as fatal
cases only those cases who died out-of-hospital (n = 203), died at the
emergency department (n = 170), or died at hospital within 7 days
after MI onset (n = 151). Deaths in the latter group occurred either at
intensive care units (n = 59), internal medicine wards (n = 35) or
any other ward (n = 57). These fatal cases (n = 524) we hereafter
refer to as 7-day fatal cases. For supplementary analyses, we considered
28-day fatal cases, comprising the 7-day fatal cases and 79 hospitalized
MI caseswhodied between day 7 and day 28 after the event. Among the
7-day fatal cases who were hospitalized and for whom clinical log data
were available (n = 42), the median hospitalization time was 3 days
(interquartile range 2–5 days); for non-fatal cases it was 6 days (inter-
quartile range 5–8 days, n = 1272).
The proportion of autopsies among 7-day fatal cases, according to
the death certiﬁcates, was 72%. From county council archives (mainly
Stockholm County) and from forensic medicine departments (in
Stockholm, except from one autopsy that took place in Uppsala), we re-
trieved 49% (n = 186) of the autopsy reports pertaining to 7-day fatalcases. Among the 186 autopsy reports retrieved, 37% were performed
by forensic pathologists. The main reason for not retrieving reports
from autopsies was that reports sometimes had been discarded due to
local restrictions regarding long-term archiving. The missing reports
should be a random sample of all autopsies.
All participating non-fatal cases were requested to complete a ques-
tionnaire which included questions about life style, body habitus, envi-
ronmental exposures, psychosocial environment, personal history of
disease and family history of disease. Participants were also invited to
attend a physical examination which took place on average 6 months
after the MI event.
2.2. Information about exposures and medical conditions
Most of the data forming bases for this study were retrieved from
questionnaires. The vast majority of non-fatal MI cases ﬁlled the ques-
tionnaires themselves. When the index case could not be contacted or
was too ill to ﬁll the questionnaire, a relative was identiﬁed and asked
to ﬁll the questionnaire in place of the case. The questionnaire was ﬁlled
by relatives in most of the fatal cases (99.7%) and in a few non-fatal
cases (1.5%). The relativeswere chosen according to the following prior-
ity order: 1) spouse or common-law spouse (49.5%), 2) children older
than 18 years old (33.6%), 3) siblings if they were younger than
80 years old (11.0%), 4) parents if they were younger than 80 years
old (0.5%), and 5) more distant relatives/friends (5.4%).
The proportion of non-fatal cases participating in SHEEP through
completing the questionnaire was 84% whereas in proxies to fatal
cases it was 62%. The numbers of MI cases forming basis for the main
analyseswere 524 7-day fatal cases and 1381 non-fatal cases. The num-
ber of participants forming basis for supplementary analyses were 603
28-day fatal cases and 1381 non-fatal MI cases.
Three additional sources were used for retrieving exposure informa-
tion in the present study: 1) physical examinations (available in 92% of
participating non-fatal cases), 2) national registers providing data on di-
agnoses at previous hospitalizations, number of previous hospitaliza-
tions and individual disposable income, 3) autopsy reports (available
in 36% of 7-day fatal cases). The information retrieved from autopsy re-
ports was, with the exception of BMI, in general based on either clinical
records or statements from close relatives.
2.3. Variable deﬁnitions
Diabetes was considered present based on either 1) questionnaire
data (report of the presence of diabetes, or report of use of anti-
diabetic medication), 2) register data (main or secondary hospital diag-
nosis of diabetes [ICD-8 or ICD-9 code 250] at any time before MI diag-
nosis), or 3) autopsy report data. Hypertension and hyperlipidemia
were correspondingly identiﬁed. The ICD-8 and ICD-9 codes used for
identifying diagnoses of hypertension were 401–404; for identifying
hyperlipidemia code 272 was used.
Body mass index (BMI) was calculated from questionnaire data on
weight in kilograms and height in centimeters. However, if such infor-
mation was available from autopsy (27% of 7-day fatal cases with re-
trieved autopsy reports) or physical examination (83% of non-fatal
cases) that information was used. Overweight was deﬁned as a BMI
value between 25 kg/m2 and 30 kg/m2, whereas obesity was deﬁned
as a BMI of 30 kg/m2 or above. Individuals with BMI greater than or
equal to 18 kg/m2, but less than 25 kg/m2were considered having “nor-
mal BMI”, and formed the reference category. Individuals with BMI less
than 18 kg/m2 (n = 25) were considered underweight and were ex-
cluded from the analyses of overweight and obesity.
Previous angina, heart failure, stroke, and intermittent claudication
were identiﬁed using questionnaire data, data retrieved from autopsy
reports or register-based information (main or secondary diagnosis)
using the following ICD 8 and ICD 9 codes: 411 and 414 (angina), 428
(heart failure), 430–438 (stroke) and 440C (intermittent claudication).
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angina, heart failure, stroke or intermittent claudication.
Individual disposable income the year preceding the year of the MI
event was obtained from Statistics Sweden. A disposable income
below the median level among participating non-fatal cases, was con-
sidered exposed to low disposable income.
Most of the questionnaire-based variables used in the present study
(physical inactivity, current smoking, family history of CVD, job strain,
working shifts and educational level) have previously been deﬁned
[19]. Parental history of premature cardiac death was deﬁned as MI or
sudden cardiac death in any parent before age 65, as reported in ques-
tionnaire or identiﬁed from the Cause of Death Register (ICD8 and
ICD9 codes 410–429; ICD9 codes 785.5 and 785.9; ICD8 code 782).
Using data from the National Patient Register (complete in
Stockholm County since 1975 and nationwide since 1987), we counted
the number of hospitalizations during the ten years preceding the MI
event as indicator of general comorbidity. Hospitalizations due to nor-
mal child delivery were not considered. We deﬁned general comorbid-
ity using the median number of hospitalizations in participating non-
fatal cases as cut-off; individuals with at least one hospitalization were
considered to have “general comorbidity”.
2.4. Statistical analysis
The risk of death within 7 days among cases (7-day MI fatality) was
calculated in different strata ofmetabolic risk factor status: diabetes, hy-
pertension, hyperlipidemia, and BMI categories. Risk ratio point esti-
mates with 95% conﬁdence intervals (CI) of 7-day MI fatality
associatedwith the different risk factors were calculated using binomial
regression with log link. Adjustments were made for age and sex in all
analyses. In subsequent analyses, additional potential confounding fac-
tors were considered for adjustments: metabolic risk factors (other
than the one under study), current smoking, physical inactivity, educa-
tional level, low disposable income, family history of CVD, parental his-
tory of premature cardiac death, general comorbidity and previous CVD.
All confounding variables were dichotomized, except BMI and educa-
tional level that were divided in four and three categories respectively.
Considering a previous observation of overestimation of level of physi-
cal inactivity by proxies to non-fatal MI cases [19], we did not include
this variable in the ﬁnal adjusted model. The remaining questionnaire-
based variables considered in the present studywere not previously ob-
served to be over- or underestimated by proxies [19]. In the ﬁnal ad-
justed model, we did not include previous CVD due to its potential
role in the mechanisms by which the metabolic risk factors under
study may affect MI fatality. MI cases who survived 7 days but died be-
fore 28dayswere excluded from themain analyses, but included in sup-
plementary analyses of 28-day MI fatality.
All statistical analyses were performed with R version 3.1.2.
2.5. Ethics statement
The SHEEP study was approved by the Ethical Committee at
Karolinska Institutet (91:259). Additional approval of the extraction of
data fromnational registers and autopsy reportswas granted by the Re-
gional Ethics Committee (2013/1731-31/1). All study participants gave
their informed oral consent to be enrolled in the study; at the time the
study was initiated (in 1992) forms for written consent were generally
not used. An invitation letter was sent by mail to eligible subjects
informing about the study. The information included description of
the rationale for the study, study aims and study design. The letter
also stated that participation was voluntary and that conﬁdentiality
was guaranteed. Close relatives of fatal cases were contacted after a
minimum of 6 months had passed after the index death; however
avoiding contact close in time to the 6 months and 1 year anniversary
of the index death. The receiver of the invitation was asked to return
the completed questionnaire by mail. Employees at the SHEEP centralreceived the questionnaires and contacted each respondent by tele-
phone, asking about clariﬁcation of unclear answers and documenting
informed consent to participate. A second letter of invitation, a re-
minder, was sent to those who did not reply to the ﬁrst letter, and the
same procedure for documentation of oral consent was used.
3. Results
Table 1 presents distributions of exposures and conditions in 7-day
fatal cases and non-fatal cases. As compared to non-fatal cases, fatal
cases were on average 2 years older and the proportion of women
was higher. Further, physical inactivity, diabetes, heart failure, previous
stroke, general comorbidity, a parental history of premature cardiac
death, low disposable income, job strain and working shifts were
more common. Obesity, current smoking and previous diagnosis of hy-
perlipidemia, hypertension, intermittent claudication, angina and edu-
cational level were similarly distributed between fatal and non-fatal
cases whereas overweight and a family history of CVD were less com-
mon among fatal cases than non-fatal cases. Treated diabetes was less
common among fatal MI (75%) cases than among non-fatal (81%).
Among cases with hyperlipidemia statins were used by 3% of non-fatal
cases and by 0% of fatal cases.
As shown in table 2, diabeteswas in crude analysis associatedwith a
52% increased risk of dying within 7 days after the MI. The risk ratios of
7-day MI fatality associated with hyperlipidemia and hypertension, re-
spectively, were close to the null. Adjustments for age, sex, and other
factors did not substantially change the risk ratio estimates.
Overweight, as compared to normal weight, was after multiple ad-
justments associated with approximately 30% decrease in risk of dying
within 7 days after the MI. For obesity, as compared to normal weight,
a similar association was observed: multiple adjusted RR 0.79 (95% CI
0.52–1.16) (Table 2). Due to the known effects by cancer on BMI, we
performed separate adjustment for previous hospitalizations with can-
cer as a primary or secondary diagnosis. The results did not substantially
change the crude result: overweight RR 0.70 (95% CI 0.56–0.89) and
obesity RR 0.85 (95% CI 0.62–1.10).
Analyses that included physical inactivity in multiple adjusted
models generated results similar in magnitude as the ones presented
in Table 2: the respective RR of MI associated with diabetes, hyperten-
sion, hyperlipidemia, overweight and obesity were 1.51 (95% CI 1.08–
2.06), 1.02 (95% CI 0.77–1.36), 0.96 (95% CI 0.72–1.26), 0.71 ( 95% CI
0.51–0.98) and 0.80 (95% CI 0.53–1.17) respectively.
Results from supplementary analyses, where adjustment for previ-
ous CVD was added to the main multiple adjusted models were similar
to the results from the original ﬁnal multiple adjustedmodels (data not
shown).
Risk ratios of 28-day MI fatality associated with the metabolic risk
factors under studywere similar to the results obtained for 7-dayMI fa-
tality, as shown in Supplementary Table 1.
4. Discussion
In the current study based on the Stockholm general population
aged 45 to 70 years, diabetes was associated with increased 7-day-
fatality in patients with ﬁrst time MI. This association was independent
of age, sex, hypertension, hyperlipidemia, overweight, obesity, parental
history of premature cardiac death, current smoking, low disposable in-
come, educational level and general comorbidity. On the other hand,
overweight was associated with a decreased 7-day MI fatality when
compared to normal BMI. Hypertension and hyperlipidemia were not
associated with MI fatality.
Our ﬁnding regarding diabetes is in agreement with two previous
population-based studies (considering hospitalized MI cases as well as
out-of-hospital CHD deaths), one based on middle-aged Finnish ﬁrst
time MI/CHD cases identiﬁed from 1988 to 1992 [10] and another
based on middle-aged ﬁrst time Australian MI/CHD cases identiﬁed
Table 1
Distribution of selected exposures and conditions among myocardial infarction cases, ac-
cording to their vital status in SHEEP.






N = 524 N = 1381
Age, mean ± SD 61.4 ± 6.8 59.5 ± 7.2 b0.001
Age, male cases, mean ± SD 60.7 ± 6.9 58.6 ± 7.1 b0.001
Age, female cases, mean ± SD 62.7 ± 6.3 61.6 ± 6.8 b0.001
Female sex (%) 182 (35.5) 413 (29.9) 0.048
Physical inactivityb (%) 223 (69.7) 635 (46.6) 0.020
Current smokingb (%) 177 (53.8) 712 (51.6) 0.644
Family history of CVDb (%) 154 (46.7) 716 (51.8) b0.001
Parental history of premature cardiac
deathb (%)
43 (12.3) 179 (8.2) b0.001
Metabolic risk factors
Diabetesb,c,d (%) 124 (23.7) 198 (14.3) b0.001
Hypertensionb,c,d (%) 187 (35.7) 536 (38.8) 0.292
Hyperlipidemiab,c,d (%) 192 (36.7) 508 (36.8) 0.961
BMI categoriesb,c,e
Normal BMI (%) 136 (44.2) 473 (34.6) b0.001
Overweight (%) 115 (37.3) 634 (46.4)
Obesity (%) 57 (18.5) 259 (19.0)
Comorbidities
Previous CVDb,c,d,f (%) 265 (50.5) 641 (46.4) 0.116
Previous anginab,c,d (%) 181 (35.1) 481 (34.8) 0.949
Previous strokeb,c,d (%) 102 (19.4) 96 (7.0) b0.001
Previous heart failureb,c,d (%) 102 (19.5) 130 (9.4) b0.001
Previous intermittent claudicationb,c,d (%) 61 (11.6) 144 (10.4) 1.000
General comorbidityc (%) 340 (66.3) 701 (50.8) b0.001
Socioeconomic and work related factors
Educational levelb
Compulsory education (%) 126 (39.0) 520 (38.0) 0.96
High school completed (%) 147 (45.5) 638 (46.6)
University studies (%) 50 (15.5) 212 (15.5)
Job strainb (%) 112 (38.8) 417 (30.0) b0.001
Low disposable incomeg (%) 326 (62.2) 691 (50.0) b0.001
Working shiftsb (%) 49 (15.8) 178 (13.1) b0.001
SD, Standard Deviation; CVD, cardiovascular disease; p value calculated using chi square
test or t test as appropriate.
a Survival for at least 28 days.
b Source of data: Questionnaire.
c Source of data: The National Patient Register.
d Source of data: Autopsy report.
e Source of data: Physical examination.
f CVD deﬁned as the presence of angina, heart failure, stroke or intermittent
claudication.
g Source of data: National register at Statistics Sweden.
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[9] population-based studies assessed diabetes near the MI event. In
agreementwith our ﬁndings on diabetes in relation toMI fatality, diabe-
tes has been reported to increase fatality in cohorts of hospitalized MI
patients [5,6,8,20].
One of several mechanisms proposed to explain why diabetes may
increase MI fatality is related to damage in large size and small size ar-
teries which in turn may reduce the blood supply in normal and in-
farcted myocardial tissue during the MI event [21]. A second
mechanism, suggested from animal models, potentially explaining
why diabetesmight have a higher fatality is related to a decreased nitric
oxide (NO) availability, which in turn may lead to vasoconstriction in-
creasing the probability of the MI becoming fatal [22]. A third mecha-
nism suggested relates to a reduction of the glucose usage by the
heart cells among diabetes cases due to decreased translocation of the
glucose transporter GLUT4 [21]. A fourth mechanism possibly
explaining the connection between diabetes and MI fatality may relate
to diabetes neuropathy that may lead to increased anginal perception
threshold, which in turn may decrease the awareness of pain duringmyocardial ischemia. A lower level of pain may cause a delay in seeking
care potentially leading to MI of large size and more prone to be fatal.
The diabetes neuropathy may even render the MI silent. Silent MI is
more common in individuals with diabetes than in those without [23].
Damaged cardiac tissue occurring after a silentMI may have adverse ef-
fect on survival of a newly recordedMI event. Thus, silent MImight be a
potentially importantmechanismof the effect of diabetes onMI fatality.
Unfortunately, we had no information on silent MIs among non-fatal
cases, thus we could not assess the importance of this mechanism.
Due to limited data on diabetes treatment, the present study could not
address whether MI fatality depends on the type of anti-diabetic
treatment.
Our results regarding overweight and obesity, showing inverse rela-
tions to MI fatality, are in line with ﬁndings reported from several pre-
vious studies based on hospital admitted MI patients [24,25]. Just as in
our study, the precision of results on obesity was inmost previous stud-
ies less than the precision of results on overweight. In a meta-analysis,
robust results of an inverse association between obesity and MI fatality
was shown [25]. In contrast, a previous population-based study (includ-
ing hospitalizedMI patients and out-of-hospital CHDdeaths) reports no
association between BMI and fatality of future CHDevents [13]. One rea-
son for the null result may be related to that BMI wasmodeled as a con-
tinuous variable which may conceal associations to MI fatality in BMI
intervals. As there is no clear understanding of biological mechanisms
that may explain why MI cases with overweight or obesity should
have better short term survival than cases with normal BMI, our results
must be interpreted with caution. In line with how Lavie et al. [26] dis-
cuss reasons for the “obesity paradox” which states that individuals
with higher BMI have a lower cardiovascular risk [27,28] and better
prognosis after a CVD event [27], from a biological perspective we spec-
ulate that our observed low 7-day MI fatality in overweight and obese
individuals, as compared to normal BMI, may be due to an attenuated
sympathetic activity of overweight individuals or to a greater metabolic
reserve. Overweight and obese patients have larger fat storages which
might serve as sources of energy that may be needed to survive a life-
threatening stressful event such as MI [29]. Another possibility is that
a certain proportion of overweight individuals, classiﬁed according to
their BMI have more muscle mass than individuals with normal BMI,
which may protect from MI fatality [26]. Hence, an anthropometric
measure that captures abdominal obesity better than BMI might have
produced different results. Further, individuals with a low BMI may be
more likely than overweight individuals to suffer from certain comor-
bidities that involve weight loss. These comorbidities may in turn de-
crease the chances of surviving an MI. Increased attention from
medical staff and increased awareness of increased risk of health prob-
lems might also be important. Despite our adjustments for general co-
morbidity there may be residual confounding in our data. For instance,
insulin resistance, usually undiagnosed, may involve weight loss and
may be associated with MI fatality. Considering that self-reported BMI,
which we have in our data, may be underestimated [30], our results
both on overweight and obesity may be diluted.
Our ﬁndings are in agreement with two population-based studies
showing no association between hypertension and MI/CHD fatality [9,
14]. Other population-based studies, however, associated hypertension
with increased MI/CHD fatality [13,16]. Findings from a number of pre-
vious studies restricted to hospitalizedMI cases agree with our ﬁndings
of no association between hypertension and short-term prognosis after
MI [6,8,11,31,32]. However, two large hospital-based American studies
show inverse associations between hypertension and MI fatality [5,
33]. One possible reason for the discrepancy between our ﬁndings and
ﬁndings from previous population-based studies that associated hyper-
tensionwith increasedMI/CHD fatality [13,16], may be related to differ-
ences in type and timing of assessments of hypertension between
studies. In our study hypertension or treatment against hypertension
was mainly self-reported or proxy-reported close in time to the MI
event, whereas in the compared studies hypertension was determined
Table 2
Risk Ratios (RR) with 95% CI of 7-day myocardial infarction fatality associated with diabetes, hypertension, hyperlipidemia, overweight and obesity.
Model Diabetes Hypertension Hyperlipidemia Overweight Obesity
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Crude 1.52 (1.30–1.90) 0.91 (0.79–1.17) 1.00 (0.75–1.30) 0.69 (0.56–0.88) 0.81 (0.65–1.09)
Adjusted by sex and age 1.45 (1.25–1.82) 0.85 (0.71–1.02) 1.13 (0.88–1.46) 0.72 (0.57–0.89) 0.88 (0.66–1.14)
Further adjustments
Current smoking 1.46 (1.15–1.81) 0.91 (0.75–1.11) 0.99 (0.76–1.30) 0.70 (0.57–0.87) 0.83 (0.63–1.07)
Parental history of premature cardiac death 1.39 (1.10–1.81) 0.91 (0.75–1.11) 1.01 (0.77–1.31) 0.72 (0.58–0.89) 0.87 (0.66–1.12)
General comorbidity 1.40 (1.16–1.68) 0.81 (0.68–1.70) 1.11 (0.87–1.43) 0.70 (0.56–0.87) 0.82 (0.62–1.08)
Previous CVD 1.48 (1.22–1.78) 0.83 (0.69–1.00) 1.10 (0.85–1.42) 0.70 (0.56–0.87) 0.82 (0.62–1.08)
Socioeconomic factorsa 1.41 (1.11–1.75) 1.03 (0.80–1.41) 0.98 (0.75–1.28) 0.64 (0.50–0.81) 0.78 (0.58–1.04)
Metabolic risk factorsb 1.70 (1.23–2.31) 1.06 (0.80–1.41) 0.98 (0.75–1.28) 0.68 (0.49–0.94) 0.79 (0.52–1.16)
Multiple adjusted modelc 1.68 (1.20–2.28) 1.04 (0.78–1.38) 0.97 (0.73–1.28) 0.68 (0.49–0.94) 0.79 (0.52–1.16)
a Adjusted for sex, age, low disposable income and educational level.
b Adjusted for sex, age, hypertension, hyperlipidemia, diabetes, overweight and obesity (except for the variable under study).
c Adjusted for sex, age, current smoking, parental history of premature cardiac death, general comorbidity, educational level, low disposable income, hypertension, hyperlipidemia,
diabetes, overweight and obesity (except for the variable under study).
34 H.K. Quintana et al. / IJC Metabolic & Endocrine 12 (2016) 30–35from blood pressure measurements at baseline investigations taking
placemany years before theMI event [13,16]. In our study hypertension
may be underestimated due to failure of identifying hypertension in in-
dividuals with unknown hypertension. This underestimation should be
equally frequent in non-fatal and fatal cases thus leading to a non-
differential misclassiﬁcation moving results towards the null. The com-
pared cohort studies, in turn, are also likely to have underestimated the
prevalence of hypertension, both in fatal and non-fatal cases, because
diagnoses of hypertension during follow-up were not considered.
Thus, results would have moved towards the null.
A limitation of the present study, as well as of any other epidemio-
logical study investigating risk factors of MI fatality, is the lack of possi-
bilities to distinguish between pre-event and post-event inﬂuences. If
our ﬁnding of an association between diabetes and increased risk of
MI fatality represents a causal relation, the effects exerted by diabetes
may either act in the pre-event phase contributing to a severe MI
more likely to be fatal, or act in the post-event phase by lowering the re-
covery capacity. A combination of pre-event and post-event inﬂuences
is also possible. Overweight, on the other hand, may theoretically con-
tribute to amild form ofMI [34] and/or positively inﬂuence the recovery
capacity. In support of obesity beingmore likely to have a role inmild as
opposed to severeMI are ﬁndings based on admittedMI patients show-
ing less severe CHD in obese patients as compared to patients with nor-
mal weight [35].
Our study has also other limitations. One of them is that the expo-
sure assessments and MI events took place about 20 years ago which
may compromise generalizability of ﬁndings to more recent settings.
However, MI fatality and the proportion of out-of-hospital deaths
among ﬁrst ever fatal CHD events have remained similar [1–2,15]. The
criteria to diagnose MI post-mortem have not changed over the years
[36]. However, the criteria for pre-mortem diagnosis of MI have
changed, mainly in that troponin is nowadays a preferred biomarker
allowing detection of smaller size MI than did previous biomarkers
[36]. Further, treatments of MI have improved leading to that severe
cases reaching hospital now more often survive the acute phase [37].
Treatments of diabetes, hypertension and hyperlipidemia have im-
proved and these risk factors are now detected earlier whichmay affect
the generalizability of results. Another limitation of the present study is
that the questionnaire data collected for fatal cases were provided by
proxies who may under- or overestimate exposure in cases. However,
according to results from a previous validation study performed based
on SHEEP data, the proxy reports on variables used in the present
study would in general agree with corresponding reports by the MI
cases themselves [19]. Misclassiﬁcation of our main exposures, if they
occurred, are thus likely to be of similar magnitude in fatal and non-
fatal cases, leading to a potential dilution of our results. An advantagewith the case-control study design is however that it allows exposure
assessments close in time to the index event.
An important strength of the SHEEP study is its well-functioning or-
ganization based on collaboration between all acute hospitals in
Stockholm County to collect all incident hospitalized non-fatal and
fatal cases. The organization also included a close collaborationwith Sta-
tistics Sweden to simultaneously identify out-of-hospital fatal MI cases
from the cause of death register. Additionally, the rate of participation
was high. The possibility to consider several relevant potential con-
founding factors in this study is another advantage. Previous
population-based studies of metabolic risk factor in relation to MI fatal-
ity had more limited possibilities to adjust for other covariates. An im-
portant strength is also the possibility we have to adjust for register-
based (and thus objective) data on disposable income and general
comorbidity.
Another strength of this study is the high proportion of autopsies in
fatal MI cases providing the opportunity to ascertain MI as a cause of
death. Previous population-based studies ofmetabolic risk factors as de-
terminants of CHD fatality did not distinguish sudden cardiac death
from fatal MI [9,10,13,14,16]. Because causes of MI fatality may differ
from causes of non-MI related sudden cardiac death, it is important
for studies addressing etiological research questions to distinguish be-
tween those.
Our results emphasize the importance of close surveillance of indi-
viduals with a diagnosis of diabetes as they may be more prone to die
would they suffer a ﬁrst MI. Preventive work should perhaps also in-
volve informing the public about the particular need for rapid hospital
admission of individuals with diabetes if an MI is suspected - even if
the pain is only moderate. Our observation of an inverse association be-
tween overweight and MI fatality may stimulate cardiovascular biology
research on potential protective mechanisms in acute MI.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcme.2016.05.009.
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